Maria V. Guijarro

Maria V. Guijarro

Auto-generated profile, based on publicly available information

Maria V. Guijarro

Department of Anatomy and Cell Biology

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2014 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MGMaria V. Guijarro
Maria V. Guijarro
SGSteven C. Ghivizzani
Steven C. Ghivizzani
CGC. Parker Gibbs
C. Parker Gibbs
Osteosarcoma (OS) is the most common non-hematologic primary tumor of bone in children and adults. High-dose cytotoxic chemotherapy and surgical resection have improved prognosis, with long-term survival for non-metastatic disease approaching 70%. However, most OS tumors are high grade and tend to rapidly develop pulmonary metastases. Despite clinical advances, patients with metastatic disease or relapse have a poor prognosis. Towards a better understanding of the molecular pathogenesis of human OS several genetically modified OS mouse models have been developed and will be reviewed here. However better animal models that more accurately recapitulate the natural progression of the disease are needed for the development of improved prognostic and diagnostic markers as well as targeted therapies for both primary and metastatic OS.

22 May 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
MGMaria V. Guijarro
Maria V. Guijarro
PKPatrick C. Kellish
Patrick C. Kellish
PDPeter E. Dib
Peter E. Dib
NPNicholas G. Paciaroni
Nicholas G. Paciaroni
ANAkbar Nawab
Akbar Nawab
MZMaria Zajac-Kaye
Maria Zajac-Kaye
Although thymidylate synthase (TYMS) inhibitors have served as components of chemotherapy regimens, the currently available inhibitors induce TYMS overexpression or alter folate transport/metabolism feedback pathways that tumor cells exploit for drug resistance, limiting overall benefit. Here we report a small molecule TYMS inhibitor that i) exhibited enhanced antitumor activity as compared with current fluoropyrimidines and antifolates without inducing TYMS overexpression, ii) is structurally distinct from classical antifolates, iii) extended survival in both pancreatic xenograft tumor models and an hTS/Ink4a/Arf null genetically engineered mouse tumor model, and iv) is well tolerated with equal efficacy using either intraperitoneal or oral administration. Mechanistically, we verify the compound is a multifunctional nonclassical antifolate, and using a series of analogs, we identify structural features allowing direct TYMS inhibition while maintaining the ability to inhibit dihydrofolate reductase. Collectively, this work identifies nonclassical antifolate inhibitors that optimize inhibition of thymidylate biosynthesis with a favorable safety profile, highlighting the potential for enhanced cancer therapy.

10 October 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
VVVinod Vijayakurup
Vinod Vijayakurup
KMKyungah Maeng
Kyungah Maeng
HLHye Seung Lee
Hye Seung Lee
BMBenjamin Meyer
Benjamin Meyer
SBSandra Burkett
Sandra Burkett
MZMaria Zajac-Kaye
Maria Zajac-Kaye
Clinical studies of cancer patients have shown that overexpression or amplification of thymidylate synthase (TS) correlates with a worse clinical outcome. We previously showed that elevated TS exhibits properties of an oncogene and promotes pancreatic neuroendocrine tumors (PanNETs) with a long latency. To study the causal impact of elevated TS levels in PanNETs, we generated a mouse model with elevated human TS (hTS) and conditional inactivation of the Men1 gene in pancreatic islet cells ( hTS/Men1 –/– ). We demonstrated that increased hTS expression was associated with earlier tumor onset and accelerated PanNET development in comparison with control Men1 –/– and Men1 +/ Δ N3-8 mice. We also observed a decrease in overall survival of hTS/Men1 +/– and hTS/Men1 –/– mice as compared with control mice. We showed that elevated hTS in Men1 -deleted tumor cells enhanced cell proliferation, deregulated cell cycle kinetics, and was associated with a higher frequency of somatic mutations, DNA damage, and genomic instability. In addition, we analyzed the survival of 88 patients with PanNETs and observed that high TS protein expression independently predicted worse clinical outcomes. In summary, elevated hTS directly participates in promoting PanNET tumorigenesis with reduced survival in Men1 -mutant background. This work will refocus attention on new strategies to inhibit TS activity for PanNET treatment.

10 September 2020 in Cells
Verified
Journal Article
Open access
PDF file
MGMaria V. Guijarro
Maria V. Guijarro
LDLaura S. Danielson
Laura S. Danielson
MCMarta Cañamero
Marta Cañamero
ANAkbar Nawab
Akbar Nawab
CACarolina Abrahan
Carolina Abrahan
GPGlyn Palmer
Glyn Palmer
TSC1 is a tumor suppressor that inhibits cell growth via negative regulation of the mammalian target of rapamycin complex (mTORC1). TSC1 mutations are associated with Tuberous Sclerosis Complex (TSC), characterized by multiple benign tumors of mesenchymal and epithelial origin. TSC1 modulates self-renewal and differentiation in hematopoietic stem cells; however, its effects on mesenchymal stem cells (MSCs) are unknown. We investigated the impact of Tsc1 inactivation in murine bone marrow (BM)-MSCs, using tissue-specific, transgelin (Tagln)-mediated cre-recombination, targeting both BM-MSCs and smooth muscle cells. Tsc1 mutants were viable, but homozygous inactivation led to a dwarfed appearance with TSC-like pathologies in multiple organs and reduced survival. In young (28 day old) mice, Tsc1 deficiency-induced significant cell expansion of non-hematopoietic BM in vivo, and MSC colony-forming potential in vitro, that was normalized upon treatment with the mTOR inhibitor, everolimus. The hyperproliferative BM-MSC phenotype was lost in aged (1.5 yr) mice, and Tsc1 inactivation was also accompanied by elevated ROS and increased senescence. ShRNA-mediated knockdown of Tsc1 in BM-MSCs replicated the hyperproliferative BM-MSC phenotype and led to impaired adipogenic and myogenic differentiation. Our data show that Tsc1 is a negative regulator of BM-MSC proliferation and support a pivotal role for the Tsc1-mTOR axis in the maintenance of the mesenchymal progenitor pool.

21 February 2014 in Postdoc Journal
Verified
Journal Article
Closed access
MGMaria V. Guijarro
Maria V. Guijarro
Osteosarcoma (OS) is the most common non-hematologic primary tumor of bone in children and adults. High-dose cytotoxic chemotherapy and surgical resection have improved prognosis, with long-term survival for non-metastatic disease approaching 70%. However, most OS tumors are high grade and tend to rapidly develop pulmonary metastases. Despite clinical advances, patients with metastatic disease or relapse have a poor prognosis. Here the cell biology of OS is reviewed with a special emphasis on mouse models as well as the roles of the cell of origin and cancer stem cells. A better understanding of the molecular pathogenesis of human OS is essential for the development of improved prognostic and diagnostic markers as well as targeted therapies for both primary and metastatic OS.